



Published in final edited form as:

J Am Coll Cardiol. 2019 December 03; 74(22): 2812–2815. doi:10.1016/j.jacc.2019.09.045.

Sex and Race/Ethnicity Differences in Atrial Fibrillation

Annabelle Santos Volgman, MD,

Rush University Medical Center, Chicago, IL

C. Noel Bairey Merz, MD,

Barbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

Emelia J. Benjamin, MD, ScM,

Boston University and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, Department of Medicine, Boston University School of Medicine; Department of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts

Anne B. Curtis, MD,

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY

Margaret C. Fang, MD, MPH,

Division of Hospital Medicine, the University of California, San Francisco (San Francisco, CA)

Kathryn J. Lindley, MD,

Washington University in St. Louis, St. Louis, MO

Carl J. Pepine, MD,

Division of Cardiovascular Medicine, University of Florida, College of Medicine, Gainesville, FL.

Marmar Vaseghi, MD, PhD,

UCLA Cardiac Arrhythmia Center, University of California, Los Angeles

Corresponding author: Annabelle Santos Volgman, 1725 W. Harrison Street, Suite 1159, Chicago, Illinois 60612, Phone 312-942-6569, Mobile 312-618-8040, Fax 312-942-4039, Annabelle_Volgman@rush.edu, Twitter: @avolgman.

Disclosures:

Bairey Merz – iRhythm Board of Directors

Benjamin – None

Curtis – Advisory board: Abbott, Janssen Pharmaceuticals, Novartis; honoraria for speaking: Medtronic, Inc., Biotronik, Novartis; data monitoring board: Medtronic, Inc.

Fang – None

Lindley – None

Pepine – None

Russo – Research trial enrollment: Boehringer Ingelheim; Clinical Trial Steering Committee: Apple (no personal financial relationships)

Vaseghi – None

Volgman – Consultant: American Heart Association; Speaker: Aptus Health

Waldo – None

Wenger – None

Twitter: Sex and racial/ethnic differences exist in Afib pts. Women and blacks have more symptoms, higher risk of strokes, procedural complications, & increased mortality compared to men. Need better outcomes and close the disparity gap!

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Albert L. Waldo, MD PhD,

Case Western Reserve University Harrington Heart & Vascular Institute, University Hospitals
Cleveland Medical Center, Division of Cardiovascular Medicine, Cleveland, Ohio

Nanette K. Wenger, MD,

Department of Medicine (Cardiology), Emory University School of Medicine, Atlanta, Georgia

Andrea M. Russo, MD

Cooper Medical School of Rowan University, Camden, New Jersey

Keywords

healthcare disparities; stroke prevention; quality of life; arrhythmia

Atrial fibrillation (AF), a worldwide epidemic, contributes to frequent hospitalizations, stroke, heart failure, disability, mortality, and health-resource consumption (1). With regards to sex, race, ethnicity, and socioeconomic status, AF affects people differently and reviews of these differences have highlighted related care disparities.

Accordingly, the American College of Cardiology's Cardiovascular Disease in Women Committee sought to compare these findings in AF patients to identify potential interventions that may help to rectify disparities of care. This writing group reviewed >200 English-language articles about these disparities to summarize them and identify important knowledge gaps. The most pertinent findings are presented here with recommendations to decrease these disparities in the future.

Globally, it is estimated that 23.1 million women and 23.2 million men had AF (atrial fibrillation and atrial flutter) in 2016, with numbers expected to rise (1). The prevalence of AF in the United States was 5 million in 2010 and is projected to be ~12 million by 2030; the cost was ~26 billion U.S. dollars in 2005 (1). Men of European ancestry have a higher incidence and lifetime risk of developing AF.

We found publications of racial/ethnic differences compared Non-Hispanic whites to blacks, as well as considerable differences by sex and socioeconomic status. Differences in sex and race/ethnicity of patients with AF exist in 1) epidemiology, 2) lifetime stroke risk, 3) mortality, 4) symptoms and quality of life, and 5) treatment. After adjustment for risk factors, compared with their white counterparts, other races/ethnicities had lower incidence rates of AF: blacks (HR: 0.84; 95% confidence interval: 0.82–0.85; Hispanics 0.78; 0.77–0.79; and Asians 0.78; 0.77–0.79; all $P<0.001$) (2).

The overall lifetime risk of AF comparing sexes appears similar, yet AF does not affect women and men similarly at any given age. The lifetime risk and age-adjusted incidence rates vary by sex, race/ethnicity, and risk factor burden. The lifetime risk of AF according to risk factor burden, after adjustment for competing risk of death at age 55 years are higher in men compared to women (optimal risk factor burden: men-29.8%: women-20.5%; borderline risk factor burden: men-39.7%: women-28.0%; elevated risk factor burden: men-43.3%: women-34.6%) (3). Whites have a higher incidence than blacks, and white men

have a higher incidence than white women for all levels of risk factor burden including smoking, alcohol consumption, body mass index, blood pressure, and diabetes (2,4). In patients with the elevated risk factor burden, the incidence rate of AF (mean age of 54.2 years old) per 1000 person-years adjusted for age, was higher in whites compared to blacks (white men-9.1: black men 6.0; white women 6.0: black women 4.1) (4).

In the Atherosclerosis Risk in Communities cohort the lifetime AF risk varied by sex in whites but not in blacks among people ages 45–55 years old (5). White men had a 36% lifetime risk of developing AF versus 30% in white women. Black women had a 22% lifetime risk of developing AF versus 21% in black men (5). The Framingham Heart Study (European ancestry) suggested that at age 55 years, the lifetime risk of AF varied by sex, as well as the presence and burden of AF risk factors as summarized in Table 1 (3). Also, white men and women have a higher lifetime risk of developing AF versus their black counterparts (5).

Women and blacks with AF are both less likely to be prescribed oral anticoagulants. Registry data found women with AF were significantly less likely to receive oral anticoagulants at all stroke risk scores using the CHA₂DS₂-VASc algorithm (1 point for Congestive heart failure, Hypertension, Age >65 years, Diabetes, Female Sex, and Vascular disease, and 2 points for Stroke and Age > 75 years) and less likely to receive oral anticoagulants than men (6). A Medicare database study (2010–11) reported that blacks and Hispanics versus whites, and women versus men, were less often given oral anticoagulation for stroke prevention, potentially contributing to the excess mortality in these groups (7).

Women compared to men, and blacks compared to whites with AF have higher mortality. In a meta-analysis of 30 studies with over 4.3 million participants, in absolute terms, AF was associated with a higher all-cause mortality in women compared to men – 1.8 [1.1 to 2.6] per 1000 patient-years (8). The study found that the pooled relative risk of all-cause mortality for those with AF versus those without AF was higher in women compared to men (relative risk 1.69 (95% confidence interval 1.50 to 1.90) versus 1.47 (1.32 to 1.65). The ratio of relative risks for women compared with men for mortality was 1.12 (95% confidence interval: 1.07 to 1.17). The excess mortality risk in women compared to men was similar in sensitivity analyses including mode of ascertainment, region, number of study participants, and year of study (8). Similarly, compared to men, women had significantly greater ratio of relative risks for several outcomes including stroke (1.99; 1.46–2.71) and heart failure (1.16; 1.07–1.27) (8). In hospitalized patients, blacks with AF have a higher mortality versus whites with AF [odds ratio: 1.90; 95% confidence interval: 1.50–2.50] (9).

Women compared to men, and blacks compared to whites, are more likely to be symptomatic with AF (10). Women and blacks with AF also have more functional impairment, more limitations in daily activities, and lower quality of life versus men. In some studies, women and blacks had lower quality of life scores even after adjustment for comorbidities (10).

In a large observational study of Medicare patients with AF from 2010–2011, women, blacks and Hispanics, compared to white men, were all more likely to receive rate control

treatment than rhythm control treatment. This was particularly true for catheter ablation versus rate control therapy (7). Another study found similar racial/ethnic treatment differences of AF. Black and Hispanic individuals were more likely to receive rate control strategy (67% in whites, 72% in blacks, and 80% in Hispanics). White men were more likely to be treated with cardioversion, antiarrhythmic drugs, and interventional therapies for AF, including catheter ablation and surgical maze procedure (10).

Knowledge Gaps

There is a significant difference in the prevalence of AF by sex, with a 3:2 male to female ratio that has not been fully explained. However, this observation does not consider age-related differences and the predominance of women in our elderly population. Addressing this sex knowledge gap could provide direction for novel approaches to forestall or even prevent the development of AF in men and women.

There is more literature reported and studied on sex differences compared to racial/ethnic differences in patients with AF. Nevertheless, in the analysis reported, it appears that there are significant racial/ethnic differences, with whites having higher rates of AF versus blacks. An overview of data on AF in sex and racial/ethnic differences indicates that women and blacks have a lower incidence and prevalence, but a poorer prognosis with AF including an increased risk for stroke, heart failure, and mortality. Reasons for these differences are unclear but genetic, socioeconomic, and other factors likely play a role. Again, addressing this gap could yield clues to the mechanism(s) of AF.

There is widespread sex and racial/ethnic differences in epidemiology, risk factors, disease manifestations, and clinical outcomes as summarized in Figure 1. Further, people of different sex, ages, races, and ethnicities have different incidences of CV disease and may react differently to AF therapies.

Summary and Conclusions

AF is a complex disease with sex and racial/ethnic differences in epidemiology, risk factors, treatment, and outcomes. Compared with white men, women and certain ethnic groups with AF often experience longer lasting and more frequent symptomatic AF episodes, have worse quality of life, have more drug-related adverse events, have lower rates of anticoagulation, have less aggressive care in terms of rate versus rhythm management, and have a higher adjusted risk of death. It is likely that the lower rates of oral anticoagulation in appropriate patients may be responsible for the higher stroke risk and worse outcomes in women and certain ethnic groups. The use of antiarrhythmic drugs requires closer follow-up than rate controlling drugs and their proarrhythmic risk may contribute to worse outcomes in patients who are not frequently monitored.

For the Future

We need to continue to increase our understanding of these differences in order to decrease disparities of care across patient populations to improve outcomes from AF in all patients regardless of sex and race/ethnicity. We suggest that as cardiologists and cardiology

organizations, our responsibilities to decrease healthcare disparities include: 1) disseminating information about healthcare disparities in AF by cardiology organizations; 2) using shared decision tools for the use of oral anticoagulation in all patients at risk for stroke and thromboembolism; 3) offering equitable treatments to decrease symptoms and improve the quality of life of all AF patients; and 4) taking measures to decrease risk from antiarrhythmic drugs such as more frequent visits and monitoring for side effects.

Acknowledgements:

We thank the following for their help with a previous version of this manuscript: Drs. Christine Albert, Charlotte Bai, Gerald Naccarelli, and Odayme Quesada. We also thank Olivia Kranz for her administrative help; Lauren Fay and Caroline Volgman for creating the table and the figure.

Funding (listed otherwise none):

Benjamin – NIH: 2R01HL092577; 1R01HL128914; American Heart Association: 18SFRN34110082, Dallas, TX

Fang – K24 HL141354 from the National Heart, Lung, and Blood Institute

Vaseghi – NIH DP2HL132356 and NIHOT2OD023848

Abbreviations:

AF atrial fibrillation

References

1. Benjamin EJ, Muntner P, Alonso A et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. *Circulation* 2019;139:e56–e66. [PubMed: 30700139]
2. O'Neal WT, Judd SE, Limdi NA et al. Differential Impact of Risk Factors in Blacks and Whites in the Development of Atrial Fibrillation: the Reasons for Geographic And Racial Differences in Stroke (REGARDS) Study. *J Racial Ethn Health Disparities* 2017;4:718–724. [PubMed: 27531069]
3. Staerk L, Wang B, Preis SR et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. *BMJ* 2018;361:k1453. [PubMed: 29699974]
4. Huxley RR, Lopez FL, Folsom AR et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 2011;123:1501–8. [PubMed: 21444879]
5. Mou L, Norby FL, Chen LY et al. Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status: ARIC Study (Atherosclerosis Risk in Communities). *Circ Arrhythm Electrophysiol* 2018;11:e006350.
6. Thompson LE, Maddox TM, Lei L et al. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR(R)) PINNACLE Registry. *JAHA*. 2017;6.
7. Bhavé PD, Lu X, Girotra S, Kamel H, Vaughan Sarrazin MS. Race- and sex-related differences in care for patients newly diagnosed with atrial fibrillation. *Heart Rhythm* 2015;12:1406–12. [PubMed: 25814418]
8. Emdin CA, Wong CX, Hsiao AJ et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. *BMJ* 2016;532:h7013.
9. Naderi S, Rodriguez F, Wang Y, Foody JM. Racial disparities in hospitalizations, procedural treatments and mortality of patients hospitalized with atrial fibrillation. *Ethnicity disease* 2014;24:144–9. [PubMed: 24804358]

10. Golwala H, Jackson LR 2nd, Simon DN et al. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. *Am Heart J* 2016;174:29–36. [PubMed: 26995367]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Epidemiology of AF in men and women by risk factor burden			
	Risk Factor Burden*		
	Optimal	Borderline	Elevated
Lifetime Risk (%) of AF in men and women according to risk factor burden, after adjustment for competing risk of death at age 55 years ^a			
Men	29.8%	39.7%	43.3%
Women	20.5%	28.0%	34.6%
Incidence rate of AF per 1000 person-years adjusted for age (mean age, 54.2 years). ^b			
Black women	0	1.7	4.1
White women	2.0	2.7	6.0
Black men	0	2.6	6.0
White men	4.0	5.2	9.1

Epidemiology and risk	
Higher incidence	White Men
Higher age adjusted prevalence	Women
Higher lifetime risk in whites	Men
Higher lifetime risk in blacks	Same in women and men
Higher risk of death from AF	Women and blacks**
Symptoms and quality of life	
Longer duration of symptoms	Women and blacks
More functional impairment and limitation of ADLs	Women and blacks
Worse quality of life scores	Women and blacks
Risk and Prevention of Stroke	
Higher risk for AF-related stroke	Women and blacks
Less likely to receive anticoagulation	Women, blacks and Hispanics
Rate and rhythm control	
More rate control than rhythm control including drugs, cardioversions, and catheter ablations	Women, blacks and Hispanics

Figure 1. Summary of sex and racial/ethnic differences in atrial fibrillation.

*In hospital mortality only. Abbreviations: ADLs: activity of daily living; AF: atrial fibrillation. a Source: Framingham Heart Study (European ancestry), at age 55 years, Staerk, 2018 (5). b Source: Atherosclerosis Risk in Communities (ARIC) Study, Huxley, 2011 (3).

**Investigators classified risk factor burden based on presence of smoking history, body mass index category, systolic and diastolic blood pressure categories, hypertension treatment, and/or diabetes category. The Framingham Study included alcohol category, but the ARIC Study did not.